Company Filing History:

28 out of 357

Gruenenthal Gmbh

where one patent can have more than one assignee

Years Active: 2005-2012

Loading Chart...

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8153795 - Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs (2012-04-10),

2. 8093272 - Heteroaryl substituted cyclohexyl-1,4-diamine compounds (2012-01-10),

3. 8088763 - Cyclohexyl-1, 4-diamine compounds (2012-01-03),

4. 8048879 - Substituted 4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine compounds and use thereof for producing medicaments (2011-11-01),

5. 7968591 - 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use in medicaments (2011-06-28),

6. 7951815 - Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds (2011-05-31),

7. 7842812 - Substituted 5-aminomethy1-1H-pyrrole-2-carboxylic acid amides (2010-11-30),

8. 7829568 - Substituted 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-ylamine compounds and their use for producing drugs (2010-11-09),

9. 7786328 - Cyclohexyl-1,4-diamine compounds (2010-08-31),

10. 7776903 - Pharmaceutical preparations containing substituted 2,5-diaminomethyl-1H-pyrroles (2010-08-17),

11. 7671074 - Sulfonylguanidine compounds and pharmaceutical uses thereof (2010-03-02),

12. 7662828 - Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds (2010-02-16),

13. 7592351 - Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds (2009-09-22),

14. 7560468 - Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds (2009-07-14),

15. 7476763 - Oxo-substituted cyclohexyl-1,4-diamine compounds (2009-01-13),

Title: Corinna Sundermann: Pioneering Innovations and Patents

Introduction:

Corinna Sundermann is a highly accomplished inventor hailing from Aachen, Germany. With an impressive portfolio of 31 patents, Sundermann has made significant contributions to the field of pharmaceuticals. This article delves into his latest patents, career highlights, notable collaborations, and the mark he has left on the industry.

Latest Patents:

Sundermann's recent patents include two groundbreaking inventions that have the potential to revolutionize drug development. The first patent pertains to "Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one compounds" and their utilization in drug production. These compounds hold promise for the creation of new and effective medicines.

The second patent showcases Sundermann's expertise in "Heteroaryl substituted cyclohexyl-1,4-diamine compounds." The invention focuses on developing novel cyclohexyl-1,4-diamine compounds and their applications in pharmaceutical compositions, as well as methods of treating certain diseases or conditions. This patent demonstrates Sundermann's dedication to advancing medical science.

Career Highlights:

Sundermann's exemplary career in innovation spans across several notable companies. Among them, Gruenenthal GmbH stands out as a significant contributor to Sundermann's professional growth. With his expertise and dedication, he has made invaluable contributions to the company's research and development efforts.

Collaborations:

Collaboration plays a crucial role in fostering innovation, and Sundermann has been fortunate to work alongside talented individuals within the industry. One notable collaborator is Bernd Sundermann, who has shared the journey of invention with him, possibly as a relative. Additionally, Hagen-Heinrich Hennies has also been a key collaborator, contributing to their collective success. Such collaborations showcase Sundermann's ability to collaborate effectively and bring ideas to life.

Conclusion:

Corinna Sundermann's extensive patent portfolio exemplifies his passion for advancing the field of pharmaceuticals. With 31 patents to his name, his expertise and dedication have left an indelible mark on the industry. His recent patents on substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one compounds and heteroaryl substituted cyclohexyl-1,4-diamine compounds demonstrate his innovative thinking and commitment towards shaping the future of medicine. Sundermann's remarkable collaborations and contributions are a testament to his prowess as an inventor. As the field of pharmaceuticals continues to evolve, Sundermann's inventive spirit promises even more exceptional achievements in the years to come.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com